Loss of Heterozygosity at the 9p21–24 Region and Identification of BRM as a Candidate Tumor Suppressor Gene in Head and Neck Squamous Cell Carcinoma

REFERENCES

• Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M. J. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2)71–96
   PubMed Web of Science ®Google Scholar
• Knudson A. G. Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993; 90(23)10914–10921
   PubMed Web of Science ®Google Scholar
• Beder L. B., Gunduz M., Ouchida M., Fukushima K., Gunduz E., Ito S., Sakai A., Nagai N., Nishizaki K., Shimizu K. Genome-wide analyses on loss of heterozygosity in head and neck squamous cell carcinomas. Lab Invest 2003; 83(1)99–105
   PubMed Web of Science ®Google Scholar
• Abou-Elhamd K. E., Habib T. N., Moussa A. E., Badawy B. S. The role of genetic susceptibility in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2008; 265(2)217–222
   PubMed Web of Science ®Google Scholar
• Nunn J., Scholes A. G., Liloglou T., Nagini S., Jones A. S., Vaughan E. D., Gosney J. R., Rogers S., Fear S., Field J. K. Fractional allele loss indicates distinct genetic populations in the development of squamous cell carcinoma of the head and neck (SCCHN). Carcinogenesis 1999; 20(12)2219–2228
   PubMed Web of Science ®Google Scholar
• Coon S. W., Savera A. T., Zarbo R. J., Benninger M. S., Chase G. A., Rybicki B. A., Van Dyke D. L. Prognostic implications of loss of heterozygosity at 8p21 and 9p21 in head and neck squamous cell carcinoma. Int J Cancer 2004; 111(2)206–212
   PubMed Web of Science ®Google Scholar
• Sheikh Ali M. A., Gunduz M., Nagatsuka H., Gunduz E., Cengiz B., Fukushima K., Beder L. B., Demircan K., Fujii M., Yamanaka N., Shimizu K., Grenman R., Nagai N. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci 2008; 99(8)1589–1594
   PubMed Web of Science ®Google Scholar
• Gunduz M., Beder L. B., Gunduz E., Nagatsuka H., Fukushima K., Pehlivan D., Cetin E., Yamanaka N., Nishizaki K., Shimizu K., Nagai N. Downregulation of ING3 mRNA expression predicts poor prognosis in head and neck cancer. Cancer Sci 2008; 99(3)531–538
   PubMed Web of Science ®Google Scholar
• Gunduz M., Ouchida M., Fukushima K., Ito S., Jitsumori Y., Nakashima T., Nagai N., Nishizaki K., Shimizu K. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Oncogene 2002; 21(28)4462–4470
   PubMed Web of Science ®Google Scholar
• Glaros S., Cirrincione G. M., Muchardt C., Kleer C. G., Michael C. W., Reisman D. The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Oncogene 2007; 26(49)7058–7066
   PubMed Web of Science ®Google Scholar
• Guo T., Sun J. The changes and significance of microsatellite loss of heterozygosity in laryngeal premalignant lesions and squamous cell carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2007; 21(18)831–833
   PubMedGoogle Scholar
• An H. X., Claas A., Savelyeva L., Seitz S., Schlag P., Scherneck S., Schwab M. Two regions of deletion in 9p23–24 in sporadic breast cancer. Cancer Res 1999; 59(16)3941–3943
   PubMed Web of Science ®Google Scholar
• van der Riet P., Nawroz H., Hruban R. H., Corio R., Tokino K., Koch W., Sidransky D. Frequent loss of chromosome 9p21–22 early in head and neck cancer progression. Cancer Res 1994; 54(5)1156–1158
   PubMed Web of Science ®Google Scholar
• Farmer T. E., Williams C. S., Washington M. K., Hiebert S. W. Inactivation of the p19(ARF) tumor suppressor affects intestinal epithelial cell proliferation and integrity. J Cell Biochem 2008; 104(6)2228–2240
   PubMed Web of Science ®Google Scholar
• Basu I., Cordovano G., Das I., Belbin T. J., Guha C., Schramm V. L. A transition state analogue of 5'-methylthioadenosine phosphorylase induces apoptosis in head and neck cancers. J Biol Chem 2007; 282(29)21477–21486
   PubMed Web of Science ®Google Scholar
• Gunduz E., Gunduz M., Ouchida M., Nagatsuka H., Beder L., Tsujigiwa H., Fukushima K., Nishizaki K., Shimizu K., Nagai N. Genetic and epigenetic alterations of BRG1 promote oral cancer development. Int J Oncol 2005; 26(1)201–210
   PubMed Web of Science ®Google Scholar
• Yamamichi N., Yamamichi-Nishina M., Mizutani T., Watanabe H., Minoguchi S., Kobayashi N., Kimura S., Ito T., Yahagi N., Ichinose M., Omata M., Iba H. The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential. Oncogene 2005; 24(35)5471–5481
   PubMed Web of Science ®Google Scholar
• Reyes J. C., Barra J., Muchardt C., Camus A., Babinet C., Yaniv M. Altered control of cellular proliferation in the absence of mammalian brahma (SNF2alpha). EMBO J 1998; 17(23)6979–6991
   PubMed Web of Science ®Google Scholar
• Reisman D. N., Sciarrotta J., Wang W., Funkhouser W. K., Weissman B. E. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 2003; 63(3)560–566
   PubMed Web of Science ®Google Scholar
• Sif S., Saurin A. J., Imbalzano A. N., Kingston R. E. Purification and characterization of mSin3A-containing Brg1 and hBrm chromatin remodeling complexes. Genes Dev 2001; 15(5)603–618
   PubMed Web of Science ®Google Scholar
• Kadam S., Emerson B. M. Transcriptional specificity of human SWI/SNF BRG1 and BRM chromatin remodeling complexes. Mol Cell 2003; 11(2)377–389
   PubMed Web of Science ®Google Scholar
• Giordani L., Iolascon A., Servedio V., Mazzocco K., Longo L., Tonini G. P. Two regions of deletion in 9p22- p24 in neuroblastoma are frequently observed in favorable tumors. Cancer Genet Cytogenet 2002; 135(1)42–47
   PubMed Web of Science ®Google Scholar
• Fukuoka J., Fujii T., Shih J. H., Dracheva T., Meerzaman D., Player A., Hong K., Settnek S., Gupta A., Buetow K., Hewitt S., Travis W. D., Jen J. Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res 2004; 10(13)4314–4324
   PubMed Web of Science ®Google Scholar
• Gunduz E., Gunduz M., Nagatsuka H., Beder L., Demircan K., Tamamura R., Hatipoglu O. F., Mahmut N., Katase N., Naomoto Y., Nagai N. Epigenetic alterations of BRG1 leads to cancer development through its nuclear-cytoplasmic shuttling abnormalities. Med Hypotheses 2006; 67(6)1313–1316
   PubMed Web of Science ®Google Scholar
• Ruusala A. Aspenström, P. Isolation and characterisation of DOCK8, a member of the DOCK180-related regulators of cell morphology. FEBS Lett, 572(1–3)159–166
   PubMed Web of Science ®Google Scholar
• Takahashi K., Kohno T., Ajima R., Sasaki H., Minna J. D., Fujiwara T., Tanaka N., Yokota J. Homozygous deletion and reduced expression of the DOCK8 gene in human lung cancer. Int J Oncol 2006; 28(2)321–328
   PubMed Web of Science ®Google Scholar
• Sarkar S., Roy B. C., Hatano N., Aoyagi T., Gohji K., Kiyama R. A novel ankyrin repeat-containing gene (Kank) located at 9p24 is a growth suppressor of renal cell carcinoma. J Biol Chem 2002; 277(39)36585–36591
   PubMed Web of Science ®Google Scholar
• Takada H., Imoto I., Tsuda H., Nakanishi Y., Sakakura C., Mitsufuji S., Hirohashi S., Inazawa J. Genomic loss and epigenetic silencing of very-low-density lipoprotein receptor involved in gastric carcinogenesis. Oncogene 2006; 25(49)6554–6562
   PubMed Web of Science ®Google Scholar